Related Experiment Videos
Radiopharmaceuticals in clinical trials
1Nuclear Medicine Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO 65201.
Seminars in Oncology
|June 1, 1993
Summary
New radiopharmaceuticals show promise for treating painful bone cancer metastases, offering a systemic radiation alternative. Most patients experienced pain relief, though transient myelotoxicity was observed in all cases.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Bone metastases often cause significant pain, impacting patient quality of life.
- Systemic radiation therapies are sought as alternatives to conventional treatments.
- Radiopharmaceuticals offer targeted delivery to bone lesions.
Purpose of the Study:
- To evaluate novel radiopharmaceuticals for treating painful bone cancer metastases.
- To assess the efficacy and safety of these agents as systemic radiation alternatives.
- To determine their potential for routine clinical use.
Main Methods:
- Development of reactor-produced radiopharmaceuticals.
- Administration of radiopharmaceuticals to patients with painful bone metastases.
- Assessment of pain reduction and toxicity profiles.
Main Results:
- Most tested radiopharmaceuticals (excluding 117mSn-DTPA) decreased or eliminated pain in over 75% of patients.
- All evaluated agents induced transient myelotoxicity.
- Three agents are currently in clinical evaluation for regulatory submission.
Conclusions:
- Radiopharmaceuticals are effective in palliating pain from bone metastases.
- Transient myelotoxicity is a manageable side effect.
- Further clinical evaluation supports potential for routine use in cancer pain management.